Heart Outcomes Prevention Evaluation
CCRE Therapeutics took part in recruitment and follow-up for the HOPE 3 which was an international randomised study evaluating the effects of the ‘polypill’ in 12,500 study participants who were without cardiovascular disease at study entry but has an intermediate cardiovascular risk, defined as a 1% annual risk of a cardiovascular event without another indication for the study medications. The polypill contained lipid and or blood pressure lowering medication (rosuvastatin, candesartan + hydrochlorothiazide, all medications, or placebo only).
With a median follow-up of 5.6 years, there was a reduced incidence of CVD outcomes for those receiving statins but not those receiving blood pressure lowering medications. HOPE-3 provides further evidence supporting broad use of statin therapy for primary prevention of CVD.
At the conclusion of the active HOPE-3 phase, most study participants agreed to passive follow-up. This was designed to provide information relating to the long-term effects of the blood pressure and lipid lowering, and see if these persist (or are enhanced). This follow-up concluded at the end of 2018 and it is expected that early 2020 will see the publication of these results.
This study was conducted by Population Health Research Institute, Canada, with funding provided by the Canadian Institutes of Health Research and AstraZeneca.